Journal of Molecular Biomarkers and Clinical Trials
Offshoring Clinical Trials
Published on: 2018-04-03
As more and more American companies offshore large randomized clinical trials—a cornerstone of evidence-based medicine— considerable debate has occurred over this practice. Hosting clinical studies in certain foreign countries can be more costeffective and allow for easier, more rapid enrollment than studies in the U.S. However, concerns about potential exploitation of vulnerable populations as well as the integrity of data and processes have come to light. Many of these concerns apply to clinical trials in general, regardless of where they take place. Our overview considers the reasons for the trend to offshoring, potential benefits of offshored trials, and concerns as well as drawbacks to this practice. Offshoring trials has the potential of increasing the speed of completion of clinical trials, which may benefit patients if this can translate into the more rapid market clearance of important treatments.
Clinical Trials; Offshoring Clinical Trials; International Clinical Trials